Symbols

EXEL

Exelixis·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Ample Liquidity

High Gross Profit Margin

Gap Up

High Cash/net Profit Ratio

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EXEL

Exelixis, Inc.

A biotechnology company

Industry

Pharmaceutical

Established Date

Listing Date

04/11/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,077

Fiscal Year Ends

12-31

Website

www.exelixis.com

Security Type

Common stock

Office address

1851 Harbor Bay Parkway, Alameda, California 94502

Business

Introduction

Exelixis, Inc., is a biotechnology company engaged in the development of small molecule therapies for cancer. The Company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc., in November 1994 and changed to Exelixis, Inc., in February 2000. The company has launched four marketed drugs, including two formulations of its flagship molecule cabozantinib. Exelixis is actively advancing its product line, and its lead clinical candidate, zanzatinib, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of colorectal cancer (CRC). The company also has a large late-stage clinical development program aimed at developing other indications. With a rational and rigorous investment strategy, Exelixis leverages its internal expertise and strong strategic partnerships to identify and seize opportunities in various scientific fields including small molecule drugs and biological therapies such as antibody-drug conjugates (ADCs).

Company Financials

EPS

EXEL has released its 2025 Q4 earnings. EPS was reported at 0.97, versus the expected 0.8, beating expectations. The chart below visualizes how EXEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EXEL has released its 2025 Q4 earnings report, with revenue of 598.66M, reflecting a YoY change of 5.63%, and net profit of 244.53M, showing a YoY change of 74.84%. The Sankey diagram below clearly presents EXEL's revenue sources and cost distribution.